---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-028126"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:57:37.641017+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals reports favorable GLP safety results for Telomir-1; IND submission targeted Q1 2026

## Summary
- No treatment-related adverse or dose-limiting toxicities observed across cardiovascular, respiratory, phototoxicity, and repeat-dose safety studies in rats and dogs.
- Telomir-1 well tolerated with consistent systemic exposure; no changes in blood pressure, heart rate, ECG, or body temperature in dogs.
- Final quality assurance review ongoing; no findings preclude advancement into first-in-human studies.
- Ongoing preclinical studies in triple-negative breast cancer and other age-related diseases; targeting IND submission Q1 2026 and first-in-human H1 2026.

## SEC filing metadata
- accession: 0001493152-25-028126
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225028126/0001493152-25-028126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225028126/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-028126
- JSON: https://secwatch.observer/filing/0001493152-25-028126.json
- Plain text: https://secwatch.observer/filing/0001493152-25-028126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.